Digital health funding in 2021 far surpassed 2020’s totals, with no signs of slowing down in 2022, and the potential permanence of some regulatory flexibilities beyond the PHE are charting a course for continued digital health growth in 2022 and beyond.
Digital health funding in 2021 far surpassed 2020’s totals, with no signs of slowing down in 2022, and the potential permanence of some regulatory flexibilities beyond the PHE are charting a course for continued digital health growth in 2022 and beyond.
Highlights
The Centers for Medicare & Medicaid Services (CMS) on April 27, 2021, released the Fiscal Year (FY) 2022 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Care Hospital (LTCH) Prospective Payment System (PPS) Proposed Rule, which will affect discharges occurring on or after Oct. 1, 2021.
The Proposed Rule would update the payment policies and annual payment rates for the inpatient payment system, update various quality programs and evaluate New Technology Add-On Payment (NTAP) applications, among other changes.
Comments on the Proposed Rule are due by June 28, 2021, and a final rule is expected by Aug. 1, 2021.
The Centers for Medicare & Medicaid Services (CMS) on April 27, 2021, released the Fiscal Year (FY) 2022 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Care Hospital (LTCH) Prospective Payment System (PPS) Proposed Rule, which will affect discharges occurring on or after Oct. 1, 2021. A CMS fact sheet is ava
Forbes)
Heart attack survivors saw no reduction in cardiovascular death and heart failure using sacubitril/valsartan (Entresto) compared with ramipril, Novartis said. More details on the PARADISE-MI trial are to be announced at the American College of Cardiology meeting later this month. (
FiercePharma)
Switching to high-sensitivity cardiac troponin testing in the emergency department was associated with more findings of myocardial injury and MI, but no overall increase in resource use (except angiography), a health system found in its Wisconsin hospitals. (
Journal of the American College of Cardiology)
Meanwhile, Roche listed new ways to use its cardiac troponin T and N-terminal pro-brain natriuretic peptide tests in identifying a person s cardiovascular risk.